Every 10-Q that Integer Holdings Corporation (ITGR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ITGR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ITGR filings page.
Integer Holdings reported second-quarter sales of $464.1 million, compared with $476.5 million a year earlier, and net income of $23.6 million, compared with $37.0 million. Gross profit was $112.9 million and operating income was $34.5 million as restructuring and other charges increased to $9.4 million, including a $5.9 million fixed asset impairment related to certain manufacturing equipment.
For the first six months of 2026, sales were $903.7 million and net income was $40.1 million, compared with $913.9 million and $14.5 million in the prior-year period. Operating cash flow was $84.4 million. Long-term debt was $1.238 billion and cash and cash equivalents were $21.4 million as of July 3, 2026; the company also completed a $50.0 million accelerated share repurchase totaling 589,605 shares.
Subsequent to quarter-end, Integer agreed to be acquired by KKR-affiliated Armstrong Parent and Armstrong Bidco for $127.00 in cash per share. The merger is subject to stockholder approval, antitrust and foreign direct investment clearances, and other customary closing conditions. If consummated, Integer would be delisted from the NYSE and become a privately held company.
Integer Holdings (ITGR) filed a 10‑Q/A (Amendment No. 1) for the quarter ended September 26, 2025 to add context to MD&A. The amendment incorporates narrative from the October 23, 2025 earnings call about sales outlook and new product adoption expected to affect the next three fiscal quarters. No changes were made to the financial statements.
For Q3 2025, sales were $467.7 million and income from continuing operations was $39.7 million ($1.11 diluted EPS). Year‑to‑date, sales were $1.382 billion with $54.2 million of income from continuing operations ($1.52 diluted EPS). Cardio & Vascular sales rose 15% in Q3, aided by contributions from the Precision and VSi acquisitions.
Management updated its sales outlook to reflect lower‑than‑anticipated demand from select emerging customers and expects 2026 declines in three new products (two electrophysiology, one neuromodulation). In March 2025, the company issued $1.0 billion of 1.875% 2030 convertible notes (net $976.1 million), used $71.0 million for capped calls, and exchanged $383.7 million of 2028 notes for $384.4 million cash and 1,553,806 shares, recording $46.7 million inducement expense. As of October 17, 2025, shares outstanding were 35,038,426.
Integer Holdings Corporation reported third-quarter 2025 results. Sales were $467.7 million, up from $431.4 million a year ago. Operating income was $56.4 million versus $58.0 million. Net income rose to $39.7 million from $35.4 million, and diluted EPS was $1.11 compared with $0.99.
For the first nine months of 2025, sales reached $1.38 billion versus $1.27 billion. Net income was $54.2 million, down from $87.2 million, reflecting higher non-operating items, including a $46.7 million induced conversion expense recorded in other loss, net. Cash from operations was $140.7 million while investing used $235.3 million and financing provided $105.3 million.
Integer issued $1.0 billion of 2030 Convertible Notes at 1.875% (initial conversion price about $150.96) and exchanged $383.7 million of its 2028 notes for $384.4 million in cash plus 1,553,806 shares. It also purchased $71.0 million of capped calls. Cash was $58.9 million, long‑term debt $1.19 billion, and equity $1.75 billion. Q3 sales included $14.9 million from 2025 acquisitions (Precision Coating and VSi), and year‑to‑date contribution was $42.1 million. Shares outstanding as of October 17, 2025 were 35,038,426.